CompletedPhase 1/2

Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)

United States88 participantsStarted 2007-01

Plain-language summary

The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of IPI-504 in patients with non-small cell lung cancer (NSCLC). The study will examine how IPI-504 is absorbed, distributed, metabolized and eliminated by the body. The study will also evaluate the anti-tumor activity of IPI-504.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically confirmed diagnosis of a Stage IIIb (with malignant pleural or pericardial effusion) or Stage IV NSCLC * Measurable disease by RECIST criteria. Exclusion Criteria: * Treatment for NSCLC with any approved or investigational product within 2 weeks of the start of IPI-504 treatment for any small molecule therapy; within 4 weeks of the start of IPI-504 treatment for any biologic or any conventional chemotherapy. * Inadequate hematologic or renal or hepatic function * Previous treatment with 17-AAG, DMAG or other known Hsp90 inhibitor.

What they're measuring

Determine potential anti-tumor activity of IPI-504 in molecularly defined sub-groups of patients by RECIST criteria

Timeframe: Every 6 weeks

Trial details

NCT IDNCT00431015

SponsorInfinity Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-08

View on ClinicalTrials.gov More Lung Cancer trials